Next Article in Journal
Ginseng for Liver Injury: Friend or Foe?
Next Article in Special Issue
Vochysia rufa Stem Bark Extract Protects Endothelial Cells against High Glucose Damage
Previous Article in Journal
Isolation and Cytotoxic Investigation of Flacourtin from Oncoba spinosa
Previous Article in Special Issue
Identification of Phlogacantholide C as a Novel ADAM10 Enhancer from Traditional Chinese Medicinal Plants
Article Menu

Export Article

Open AccessArticle
Medicines 2016, 3(4), 32; doi:10.3390/medicines3040032

Study Protocol for a Randomized Double Blind, Treatment Control Trial Comparing the Efficacy of a Micronutrient Formula to a Single Vitamin Supplement in the Treatment of Premenstrual Syndrome

Department of Psychology, College of Science, University of Canterbury, Private Bag 4800, Christchurch 8041, New Zealand
*
Author to whom correspondence should be addressed.
Academic Editor: James D. Adams
Received: 12 August 2016 / Revised: 4 November 2016 / Accepted: 15 November 2016 / Published: 7 December 2016
(This article belongs to the Special Issue Herbal Medicines and Functional Foods)
View Full-Text   |   Download PDF [477 KB, uploaded 7 December 2016]   |  

Abstract

Background: The recent addition of Premenstrual Dysphoric Disorder (PMDD) to the Diagnostic and Statistical Manual (5th ed.) has highlighted the seriousness of this disorder. Many alternatives to psychoactive medication in the form of vitamins, minerals, and plant extracts have been trialled by women seeking a natural treatment approach. We plan to explore whether a well validated micronutrient formula, EMPowerplus Advanced, can outperform a recognized single nutrient treatment, vitamin B6, for the treatment of Premenstrual Syndrome (PMS). Methods: This will be a randomized treatment control study. Eighty women will be recruited and assigned to one of two treatment groups; EMPowerplus Advanced or vitamin B6. Baseline daily data will be collected for an initial two cycles, followed by three months of active treatment. A natural follow up will take place three cycles post treatment. Results: The primary outcome measure will be PMS change scores as based on results from the Daily Record of Severity of Problems (DRSP). The number of treatment responders for each of the two groups will yield a comparison score between the two treatments, with participants deemed as a responder if they show a total PMS score improvement of 50% from their baseline scores on the DRSP. Conclusion: If a micronutrient formula proves more effective for treating PMS, not only does it give women suffering from the condition a viable treatment option, but it may also suggest one cause of PMS; that is insufficient minerals and vitamins. View Full-Text
Keywords: premenstrual syndrome; premenstrual dysphoric disorder; treatment; vitamins; minerals premenstrual syndrome; premenstrual dysphoric disorder; treatment; vitamins; minerals
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Retallick-Brown, H.; Rucklidge, J.; Blampied, N. Study Protocol for a Randomized Double Blind, Treatment Control Trial Comparing the Efficacy of a Micronutrient Formula to a Single Vitamin Supplement in the Treatment of Premenstrual Syndrome. Medicines 2016, 3, 32.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Medicines EISSN 2305-6320 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top